Please go to our new page for Transvaginal Mesh and More Updates
Rank 30 Jan, 2012 = 4/158,000
5 January, 2012 - NEW ARTICLE
Our series on transvaginal mesh is now in PDF format, 26 pages.
Rank 30 Jan, 2012 = 4/158,000
5 January, 2012 - NEW ARTICLE
Our series on transvaginal mesh is now in PDF format, 26 pages.
That's 2.0 percent more profit and 6.0 percent more revenues than during the same period last year, when Murray Hill, N.J.-based Bard reported profits of $127.5 million, or $1.34 diluted EPS, on sales of $678.4 million. October 26, 2011 by MassDevice
FDA Safety Communication: UPDATE on Serious Complications Associated with
Transvaginal Placement of Surgical Mesh for Pelvic Organ Prolapse
Boston Scientific and other transvaginal mesh makers defend their devices amid FDA probeBoston Scientific urges the FDA to maintain a class II device status on transvaginal mesh amid calls from public advocates for product recalls and FDA warnings that the devices may do more harm than good.
Johnson & Johnson vaginal mesh lawsuits another blow to the FDA's device review process
October 20, 2011 by Arezu Sarvestani
With high profile recalls in hip implants and defibrillators in the recent past, the FDA's medical device review process takes another hit it doesn't need as health care giant Johnson & Johnson weathers a storm of transvaginal mesh complaints.
FDA's medical device review process is again under scrutiny as lawsuits pile up against health care leviathan Johnson & Johnson (NYSE:JNJ) for transvaginal mesh devices that may do more harm than good.
Lawsuits claiming negligence against mesh-makers have also implicated the FDA's review system for continuing to clear new mesh products under the 510(k) system, despite the predicate device being pulled from U.S. shelves.
from Bloomberg By - J&J Vaginal Mesh Approved by FDA Based on Similar Device Recalled in 1999
More from the FDA
September 29, 2011
I am excited to report that I will be doing some follow up stories for an old friend, Eric Chaffin, of Chaffin Luhana LLP about prolapse and vaginal mesh complications. Eric is the one who originally approached me about doing the below vaginal mesh series a couple of years ago when he was with his old law firm. Eric and his now law partner, Roopal Luhana, have their own firm in NYC, Chaffin Luhana LLP. Eric and Roopal were some of the first attorneys in the country to represent women in the Bard Avaulta mesh litigation and in Gynecare mesh lawsuits. They continue to represent women in these medical device cases, as well as in other vaginal mesh litigations, including representing women in cases against Boston Scientific and American Medical Systems regarding allegedly defective vaginal mesh. You can learn more about the vaginal mesh cases Chaffin Luhana is handling through the vaginal mesh information website that Chaffin Luhana sponsors. I also hope that you will visit us soon here at Natural Health News to read the first of what I anticipate will be a multiple part follow up series regarding vaginal mesh.
Original and complete article from 2009 about TV Mesh Has Moved in order to bring you more updates on this important health issue.
UPDATE: 19 June, 2011
Several years ago I was commissioned by a consumer injury law firm to write a series of articles. One of those articles, http://naturalhealthnews.blogspot.com/2009/03/transvaginal-mesh-and-womens-health.html addressed issues with the transvaginal mesh device. This article is also found on our other websites, simply4health.org and leaflady.org.
In the past several months I have noticed an increasing number of TV ads for this device from consumer injury law firms. I have also noticed a viral spread of this article which has booted the reader ship of my blog, Natural Health News, by thousands of readers daily.
This tells me that many women must be very interested in this topic, either because they have had this surgery and are facing problems, or they have been advised to have this operation.
Alternatives to the surgery are available options. I hope to educate you about an important one that can do a great deal to prevent and correct this condition.
Should you wish a copy of this new article please email us and request it.
Please consider a donation to help us continue this important work.
As originally written in 2009, in cooperation with Eric Chaffin, this article has created an internet storm -
Originally posted March 2009 -
Transvaginal Surgical Mesh Origins
Polypropylene was first developed in the 1950s as a thermoplastic polymer resin of propylene and is made from petroleum. Polypropylene may be molded or extruded into many forms, including fibers for suture material, specially produced mesh and nonwoven sheet applications. Nonwoven polypropylene fabric later began to be extruded from polymer melts rather than from fibers.
New MESH page has the complete article and much more information.
Quaternary ammonium biocides are used as a disinfectant and germ killing substance because they disrupt the cell membrane and proteins. QUATS may not, however, be fully effective against Pseudomonas bacteria. Also, researchers have found in laboratory experiments that oleamide, which interacts with neurotransmitters, may leak out of polypropylene plastics.
Polypropylene Knitted Mesh (PPKM) fabrics are comprised of monofilament yarns, which are engineered for the manufacturing of textile fabrics. The polymer and manufacturing processes that are used produce fabrics with properties that are ideally suited for the manufacturing of medical device applications. Medical applications include hernia mesh patches, stress urinary incontinence (SUI) slings, and vaginal prolapse suspenders.
Nonwoven polypropylene fabric has been used for similar applications.
Problems with polypropylene fabrics have led to warnings being issued for various products made from nonwoven material and in some cases, the manufacturers have stopped marketing the products
According to adverse reports submitted to the FDA from nine different manufacturers, more than 1,000 people have suffered severe complications from surgical mesh implants. The reports include infection, pain, urinary problems and bowel, bladder or blood-vessel perforations. The repaired prolapse may have recurred or incontinence increased. Additional surgeries to remove mesh have been required because of vaginal erosion.
Transvaginal Surgical Mesh to Treat SUI
Sudden Urinary Incontinence (SUI) is estimated to affect as many as 11 million women in the United States. It is generally defined as the sudden, involuntary loss of urine when a patient is laughing, sneezing, coughing or exercising. SUI is caused by anything that may have led to serious pelvic muscle strain or weakness such as vaginal childbirth. It can be exacerbated by estrogen and other hormonal imbalance accompanying menopause.
Nearly 40% of all adult American women will experience various degrees of SUI during their lifetime. Symptoms can range from occasional leakage of a few drops of urine to complete loss of urine under certain conditions of stress. Although nonsurgical methods such as dietary changes, bladder retraining, Kegel exercises, biofeedback, pessaries, electrostimulation, and drug therapies have been used successfully to treat these women, many patients eventually require surgical repair to relieve their symptoms.
Historically, and for many decades, the Kelley plication or the Marshall-Marchetti (Krantz) procedures have been the main hospital based surgical treatments for reinforcing the bladder neck in order to prevent unintentional urine loss.
Other surgical techniques have been used to correct pelvic organ prolapse (POP), a related condition.
Transvaginal Surgical Mesh to Treat POP
The problem of incontinence for women from various causes becomes more common after pregnancy and in menopause, when surgery can be recommended after other non-intrusive treatments are not found effective.
These conditions are referred to as Pelvic Organ Prolapse(POP).
POP is the term that describes a condition when a pelvic organ drops from its normal location and pushes against the walls of the vagina. This generally occurs when muscles that hold pelvic organs in place are weakened or stretched by childbirth or surgery. POP can lead to symptoms that include pain, discomfort, loss of bladder control and constipation.
One popular product, known as the transobturator vaginal sling, was made by Mentor Corporation. This product was more commonly called “OB Tape.”
Mentor manufactured an OB Tape vaginal sling that was not recalled, but the company stopped marketing it in the spring of 2006. The product used a nonwoven material which made it different in design than most other mesh devices. The nonwoven fabric is alleged to have blocked oxygen and nutrients, substantially increasing the risk of problems such as infection. This impedance potentially can cause serious problems with the device that may not appear for months, or even years following implantation surgery.
The complication rate could very easily reach 20% of all patients who used the Mentor sling.
At least 35,000 women may have been treated with the OB Tape vaginal sling between 2003 and 2006 to treat female stress urinary incontinence (SUI). The bladder sling is designed to prevent involuntary leakage that occurs when pelvic muscles supporting the bladder and urethra are stressed or weakened. A number of women have filed Mentor sling lawsuits.
A study published in the Journal of Urology in October 2006 highlighted the risk of complications associated with the OB Tape sling. More than 13% of the women who received the Mentor Sling for incontinence allegedly have suffered vaginal extrusions. Many more cases reported women who suffered chronic vaginal discharge and abscesses.
Symptoms of OB Tape Sling injury may include but are not be limited to:
· High fever
· Vaginal Pain
· Pelvic Pain
· Pain During Sex
· Chronic Infections
· Perineal Cellulitis
· Severe Pain in the Back, Hips and Legs
If you have had this surgery and are experiencing any of these or other symptoms not listed here, immediately contact your health care provider.
If you have suffered an injury or Mentor sling side effects from surgery involving the use of a Mentor sling, and would like to learn about your legal rights and pursuing a Mentor sling lawsuit, you can find information at Consumer Injury Lawyers.
Other Transvaginal Surgical Meshes
Another product, Gynecare’s Prolift Sling, created serious problems that required additional surgery that has caused permanent injury. The Avaulta Bard surgical mesh, which is used to treat POP and SUI have also been the subject of Avaulta transvaginal mesh lawsuits. It has led some consumer advocates to call for an Avaulta transvaginal mesh recall.
If you have had a prolene mesh pelvic floor repair system and have suffered complications, you may have a viable product liability claim. In October 2008 the FDA transvaginal mesh alertwas issued for at least nine manufacturers of vaginal sling products.
Overall use of these surgical mesh products has been associated with severe and debilitating injuries including vaginal extrusions, urinary tract erosions, infection and nerve pain. Other known complications include, but are not limited to, mesh erosion, mesh shrinkage, granuloma from tissue injury or dyspareunia (pain with sexual relations).
Product and procedure failure with the tape sling products have required additional surgeries to remove the mesh, along with an increased risk of more injury.
If you have suffered an injury from any surgery involving the use of the surgical meshes referred to in the above article and would like to learn about your legal rights, you can find information from Consumer Injury Lawyers, a consumer advocacy legal website that provides helpful information to consumers about various drugs and medical devices, including for example information about the recent reports of zinc poisoning caused by denture cream, including information about denture cream lawsuits such as how to file a Fixodent lawsuit orPoligrip lawsuit.
This article is part of a consumer health education series written by Gayle Eversole, DHom, PhD, MH, NP, ND, of Creating Health Institute, in collaboration with Bernstein Liebhard, LLP.
The views expressed in this article are solely those of the author, Gayle Eversole.